Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes
New onset of diabetes · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) showed no clear difference in new‐onset diabetes mellitus compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).
1 finding from 1 review
- Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes onlyRR 0.93 [0.69, 1.26]13 studies · 2791 participantsModerate